Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
Additional Results Showing Statistically Significant Improvement in Amputation-Free Survival to be Presented by Principal Investigator Richard Powell, M.D.; Webcast and Conference Call Scheduled for 3:30pm EDT
ANN ARBOR, Mich., June 8, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Scott C. Durbin has joined the company as chief financial officer. Mr.
ANN ARBOR, Mich., June 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Conference call and webcast of the presentation of interim results from Aastrom's U.S. Phase 2b RESTORE-CLI clinical trial which will be presented at the Vascular
ANN ARBOR, Mich., May 27, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Ronnda Bartel, Ph.D., chief scientific officer, will participate in a plenary
ANN ARBOR, Mich., May 17, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S.
ANN ARBOR, Mich., May 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also
Webcast Alert: Aastrom to Host Investor Conference Call on Critical Limb Ischemia and Related Clinical Development Progress Ann Arbor, Michigan, May 3, 2010 (3:20 pm ET) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following webcast: What: Investor conference call to present an update
Principal Investigator Dr. Richard Powell to Present Interim Results From U.S. Phase 2b RESTORE-CLI Trial at the 2010 Vascular Annual Meeting(R) on June 11 in Boston, MA
